CD274 and non-small cell lung carcinoma: For the 16 391 patients diagnosed with NSCLC and part of 48 RCTs, the platinum regimen + Pemb and the platinum regimen + Niv + Ipi were considered appropriate first‐line agents for treating squamous NSCLC with low PD‐L1.